The concept that chromosome abnormalities are exclusively related to malignant cells clearly has to be revised.
A variety of specific chromosome changes have now been identified in several benign neoplasms (Table 1) and certain chromosome regions seem to be non-randomly affected. The most frequently altered areas include: 1) the 12ql3-ql5 region in typical lipomas, uterine leiomyomas, pleomorphic adenomas of salivary gland and recently also in endometrial polyps [4] ; 2) the terminal region of the short arm of chromosome 6 in lipomas, uterine leiomyomas and also in endometrial polyps [5] ; 3) the 13ql2-q22 region in lipomas and uterine leiomyomas; 4) an extra chromosome 12 in uterine leiomyomas and benign ovarian tumors, i.e. fibroma, thecomas, and fibrothecomas [6] . By definition, the major difference between benign and malignant tumors is the ability of the latter to invade and metastasize. It appears likely that as additional insights are gained regarding the molecular changes underlying chromosome alterations, new insights into the progression of malignancy will arise.
2. Cytogenetic findings can be used today by the pathologist, and oncologist to assist in assigning the correct diagnosis of tumors lacking either a specific marker of cellular differentiation or displaying a characteristic histology.
A specific example of tumors in which cytogenetics may be useful are the childhood cancers, Ewing's sarcoma, neuroblastoma, and rhabdomyosarcoma, where correct diagnosis is difficult to achieve because of a virtually identical microscopic picture of the undifferentiated cells. Several new methods help in establishing ther correct diagnosis of these tumors, of which cytogenetics is one [7] . All these tumors demonstrate unique chromosomal changes A t(2;13)(q35-37;ql4) or its variant t(l;13)(p36;ql4) has been mainly associated with alveolar rhabdomyosarcoma [8, 9] . Neuroblastomas are characterized either by loss of the terminal region of the short arm of chromosome 1 (mainly Ip32-lp36) or by double minute chromosome or homogeneously staining regions (resulting from gene amplification of N-myc) [10] . A reciprocal translocation between chromosomes 11 and 22, t(ll;22)(q24; ql2) has been found in 92% of Ewing's sarcoma cases and also in peripheral neuroectodermal tumors [12] . For example, transitional cell carcinoma of the bladder histologically appears to be a rather uniform tumor. CytogeneticaLly, it has been possible to define several subgroups, each characterized by a specific chromosome change such as i(5p) or 5q-, +7, -9 or 9q-, Up- [13] . At least 7 cytogenetically distinct subgroups have been described in uterine leiomyoma; those with involvement of 12ql4-15, 6p21-pter those with 7q-, 13q-, those with t(l;2), trisomy 12 and those with a normal karyotype [14] . Histologically these subgroups are indistinguishable, as is the case in lipoma-subgroups [15] . These findings may suggest that each subgroup may ultimately correlate with specific parameters such as course of the disease, stage an grade of the cancer, anatomic site of the tumor, biological behavior, response to therapy or to hormones, recurrence, survival, etc. The occurrence of one or more copies of an isochromosome of the short arm of chromosome 12, i(12p), is striking and apparently characteristic of 80% of the germ cell tumors (GCTs) not only of the testis, but also in ovarian and extragonadal GCTs. This finding sug-gests that through an unknown mechanism of a specific chromosome change may occur in an undifferentiated gonocyte [16] . The t(ll;22)(q24;ql2) originally described in Ewing's sarcoma, was also found in peripheral neuroectodermal tumors (PNTs) [17] , Askin tumor [18] , esthesioneuroblastoma [19] , neuroendocrine tumor of the small intestine [20] , and extraskeletal Ewing's sarcoma [21] . These cytogenetic findings provide support for a common neuroectodermaJ origin of all these malignancies [22] .
Of all solid tumors, sarcomas have the highest
degree of specificity of chromosome alteration since they are associated with defined rranslocations specific to each histopathologically recognizable tumor subtype.
A specific translocation between chromosomes X and 18 t(X;18)(pll.2;qll.2) characterizes synovial sarcoma, primary or recurrent or metastasis, whatever the histologic pattern, i.e. biphasic, monophasic or poorly differentiated [23] . A t(12;16)(ql3;pll) has been found to be restricted to myxoid liposarcoma whereas long marker, ring(s) occur in well-differentiated liposarcoma [24] .
Clear cell sarcomas, also known as 'melanoma of the soft parts' have recently been characterized by a t(12;22)(ql3;ql2) [25] . Table 1 Although the value of chromosome analysis has been well established in hematologic malignancies, the relationship between chromosome abnormalities and clinical outcome in most solid tumors has received little study. Nevertheless, several recent studies have provided preliminary information of the relationship of cytogenetic abnormalities and clinical outcome in solid tumors [26, 27] . Because there is a large number of comparisons necessitated by the design of these studies (e.g., comparison of clinical parameters with multiple chromosome rearrangements), the general significance of these results are still unclear and require further corroboration. However, based upon the clinical utility of the blood-borne cancers of man, it seems likely that analysis of solid tumors will prove to be of similar clinical value.
Summary and future perspectives
The exact role of chromosome abnormalities in human cancers clearly requires additional study. However, there is significant information now implicating cytogenetic rearrangements as early and perhaps causative changes in some human cancers. Of clinical relevance, information which is continuing to accrue in both hematologic and more recently solid tumors provides evidence that clinically useful information will indeed be forthcoming. We believe that with the continued focus on cytogenetic analysis of solid tumors (coupled with the tremendous emphasis now on fluorescence in situ hybridization) new karyotypic information will be forthcoming and is likely to be of distinct value to clinical oncologists.
